Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
Recruiting · NCT03263130 · Observational (researchers observe without assigning treatment) · Lead sponsor: Gelb, Arthur F., M.D.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).
Who can take part
Inclusion criteria
- asthma- copd overlap
- emphysema in smokers with smoking history \> 15 pack years
- COPD/ bronchitis and bronchiectasis in smokers with smoking history
- \>15 pack years
Exclusion criteria
- ther pulmonary or systemic diagnosis
- non smokers
- any other pulmonary diagnosis
- pulmonary fibrosis
Where it is running
2 locations listed across 1 US state.
- Arthur F Gelb MD - Lakewood, California, United States
- Arthur F Gelb MD - Lakewood, California, United States